NEW YORK (GenomeWeb) – Castle Biosciences today announced it has secured a $6 million credit facility from Silicon Valley Bank.

The funding will be used to support commercial and clinical activities for the firm's cutaneous melanoma test called DecisionDx-Melanoma for determining the metastatic risk of patients with melanoma, Castle President and CEO Derek Maetzold said in a statement. The financing will also be used for general operations. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.